about
The perils of not digging deep enough--uncovering a rare cause of acquired anemiaHematologic effects of antimicrobials: focus on the oxazolidinone linezolid.Linezolid-Induced anemia and thrombocytopenia.Hematologic effects of linezolid: summary of clinical experience.Mechanisms for linezolid-induced anemia and thrombocytopenia.Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.Sideroblastic anaemia during fusidic acid treatment.Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolidClinical experience of linezolid in bone marrow transplantation patients.Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation.Probable linezolid-induced thrombocytopenia in a patient with vancomycin-resistant enterococci.Long-term treatment with linezolid in a patient with osteomyelitis undergoing hemodialysis.High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.Clinical population pharmacokinetics and toxicodynamics of linezolid.Thrombocytopenia in Patients Receiving Prolonged Linezolid May be Caused by Oxidative Stress.Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection.Desensitization protocols for vancomycin hypersensitivity.Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studiesMycetoma medical therapy.Role of linezolid in the treatment of orthopedic infections.Current use of anti-infectives in dermatology.Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates.Bell's palsy associated with linezolid therapy: case report and review of neuropathic adverse events.Emerging cephalosporins.The evaluation and treatment of complicated skin and skin structure infections.Complications of MRSA Treatment: Linezolid-induced Myelosuppression Presenting with Pancytopenia.New treatment options for multidrug-resistant tuberculosis.Linezolid: a promising option in the treatment of Gram-positives.Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation.In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.Probable linezolid-induced pancytopenia.In vivo efficacy of a novel oxazolidinone compound in two mouse models of infectionActivity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay usi
P2860
Q28254062-B616A2CE-3899-4FF8-ABE0-0AA76350BFEDQ33339926-8C2D45EB-BADA-4BE0-B21F-A711E00280E7Q33340618-61B8ABDA-84B1-4932-8CB1-0016746355F9Q33343252-DE18FEA9-E122-404B-96E1-8D91FEA84C29Q33347167-C1F469A3-15F1-4DB2-BEC2-14B6F7398C61Q33358278-ADED81DF-7A6C-4212-B4CE-97403D3442B0Q33360246-AC9097E4-2797-4DD4-9169-3885C42720A7Q33375091-3168A706-1383-4870-9309-3F1B4A395A04Q33394990-D52539FA-3D4D-49BB-AD44-45DD5A88ABDCQ33400641-910B63D6-8E5A-426E-AF9C-68C735B6F573Q33400991-732D1AB6-2994-4AC3-92F8-9A30577CD0C4Q33403692-CBCF6FE6-CE0E-42BA-89EA-0052614AEEC2Q33407349-46E8EC49-498E-40C2-973A-468649D15B3CQ33410244-3AAB4FC1-3A1D-4B73-BA96-7C302E41CB6CQ33413269-5F555C06-612D-493F-834C-009284E239E8Q33427112-B379C557-91B5-4E10-A694-4E9AA3925F0FQ33435423-FFF3C56B-9B10-48CF-8B43-49B4772A6FA5Q33439246-0F0A17E7-6CAE-44CE-8EB7-DC90EC2E44B1Q33559139-1E57E540-E8EE-407C-8E47-70016D458AD7Q34110412-541DFD4F-7382-447B-9AF8-3FDF6AC29419Q34252432-DF36D1A2-0187-40B0-ABEC-6302DD74AEC9Q34371909-570BCBB7-1B3F-47BE-89F5-46D2E7562B66Q34449467-A88ECEEB-9BEF-4A78-A046-42BC3D4F93F2Q35013856-CE180C74-0ECD-4C6C-A580-FA06E8501840Q35351362-E5D92EC0-9A3A-4790-AD9C-9EDB7EC1811DQ36162348-729A8F52-BD67-4CF1-B34C-BD652F1F9FC4Q36233506-51F88A8A-7EA1-4C40-B033-A18A8CEC4216Q36492132-9AC76C58-5E7D-4132-B808-9B6DF8CEAB52Q36545088-C04459E4-F620-4A05-9A4F-266F5808FC31Q36989896-9956B618-B8DB-4AD7-9324-DAEFA5A13B00Q37111836-5ABAEA63-9578-4F8B-9B98-35C7FD73DC97Q37166936-D095C3DD-2725-473E-809F-E824F9B6A2EFQ38024041-303580F7-82B8-4A78-857A-2AC4D930086BQ39044932-4E98EC4D-47C9-40BD-9265-F26ACA0525B7Q39109101-33898C58-2D9B-4209-A347-D83EF939DD99Q39479010-AD433074-E4FC-4E88-82C5-FA97A39A8592Q40211387-B29A69FA-04BC-4068-B0A4-F01AB9FCEC08Q40671237-96FFB0DA-BFE2-4037-ACFC-FA1E059B3A92Q41767104-0A3F672B-0C78-4802-964E-72445AC38978Q42003344-3661F091-6B6B-4010-8EA4-6260F3836870
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Linezolid and reversible myelosuppression.
@en
type
label
Linezolid and reversible myelosuppression.
@en
prefLabel
Linezolid and reversible myelosuppression.
@en
P2093
P356
P1476
Linezolid and reversible myelosuppression.
@en
P2093
E D Huttenbach
J C Maddox
P356
10.1001/JAMA.285.10.1291
P407
P577
2001-03-01T00:00:00Z